Randomized Trialhigh evidence
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
The Lancet. Neurology·August 1, 2026·PMID 42456682
Why it mattersCurrent dopamine agonists target D2/D3 receptors and are associated with non-motor side effects like somnolence and impulse control disorders. Tavapadon is a selective D1/D5 agonist that may offer motor benefit with a different tolerability profile, potentially expanding early treatment options.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled